ev3 and the ev3 logo are trademarks of ev3 Inc., registered in the U.S. and other countries.
All trademarks and trade names referred to in this press release are the property of their respective owners.
About FoxHollow Technologies
FoxHollow Technologies, Inc. develops and markets minimally invasive devices for the removal of plaque and thrombus for the treatment of peripheral artery disease (PAD). PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The company's SilverHawk Plaque Excision System is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet. The company's Rinspirator thrombectomy system removes thrombus, or blood clots, from occluded arteries in patients suffering from PAD or coronary artery disease.
Forward-Looking Statements
This communication contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995. Such
statements include, but are not limited to, statements about the benefits
of the business combination transaction involving ev3 and FoxHollow, the
integration of the two businesses, potential synergies and cost savings,
future financial and operating results, ev3's plans, objectives,
expectations and intentions with respect to future operations, products and
services; and other statements identified by words such as "anticipate,"
"believe," "plan," "estimate," "expect," "intend," "will," "should," "may,"
or words of similar meaning and any other statements that are not
historical facts. Such forward- looking statements are based upon the
current beliefs and expectations of ev3's management and are inherently
subject to significant business, economic
'/>"/>
| SOURCE FoxHollow Technologies, Inc. Copyright©2007 PR Newswire. All rights reserved |